Developer docs
API playgroundTry for free, no card

Search company profiles

Indomo

Full company profile

uuid003qhv4

Namestring
Indomo
Legal namestring
ACOM Labs, Inc.
Websiteurl
indomotx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Indomo (doing business as ACOM Labs, Inc., a Delaware-incorporated corporation headquartered in Boston with a San Francisco mailing address) is a clinical-stage therapeutics company developing a drug-device combination platform for at-home treatment of inflammatory acne lesions. The company's core offering, the ClearPen™ System, pairs a novel intradermal self-injection device (ClearPen) with a corticosteroid drug candidate (DT-001, based on triamcinolone acetonide) to enable patients to self-administer intralesional injections at home, replicating a procedure that has been the in-office dermatology standard of care for 50+ years and is recommended by the American Academy of Dermatology.

The underlying technology combines a patented intradermal self-injection mechanism designed to control dosage, depth, and volume with a reformulated corticosteroid drug candidate. Indomo has completed two investigator-led trials and a sponsored n=56 trial demonstrating equivalence between patient self-injection and provider injection with zero adverse events and significant lesion improvement reported by over two-thirds of participants within 24 hours. Phase 2 clinical trials are planned for 2026, with DT-001 manufacturing contracted to Lifecore Biomedical under a development services agreement signed in March 2026.

The company is pre-revenue with no commercial products, no FDA approval, and no disclosed pricing. Its go-to-market motion is product-led, targeting the underserved patient population of 50 million Americans affected by acne who lack access to dermatologists or prefer at-home treatment. Indomo maintains a clinical trial waitlist as its primary mid-funnel conversion mechanism, and the planned commercial model appears to be direct-to-consumer distribution of the combined device-plus-drug system. The company raised $25 million in late 2025 led by Atomic, Foresite Capital, and Polaris Partners to fund clinical development and platform expansion.

Short descriptiontext

Indomo is a clinical-stage therapeutics company developing the ClearPen System, a drug-device combination of an intradermal self-injection device and DT-001 corticosteroid, enabling at-home self-administered treatment of inflammatory acne lesions for the 50 million Americans affected by acne.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug-device combination, intradermal injection, acne therapeutics, self-injection devices, dermatology treatments
Industry1 code
PRIMARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Pharmaceutical Preparations2834
Product category
Dermatology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1ClearPen System (DT-001 + Device)
TypeHardware Sales
Description

Clinical-stage company developing a drug-device combination product. The ClearPen system combines DT-001 corticosteroid with a self-injection device for at-home acne treatment. Revenue model not yet disclosed as products are under development and have not been evaluated by FDA or any regulatory authority.

pulse2.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Indomo is developing the ClearPen™ System, a drug-device combination platform that pairs the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device. The system is designed to enable patients to self-administer intralesional acne injections at home, replicating the in-office standard of care for moderate to severe inflammatory acne lesions. Indomo's products are currently under development and have not been evaluated by the FDA or any regulatory health authority.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over two-thirds of participants reported significant improvement of lesion within 24 hours
+2 more records
Product overview1 text field

Indomo is a clinical-stage therapeutics company developing a drug-device combination platform for at-home dermatological treatments. The company's primary offering consists of the ClearPen™ intradermal self-injection device combined with DT-001, a corticosteroid drug candidate. Together, this device-plus-drug platform enables patients to self-administer intralesional injections for inflammatory acne lesions at home, shifting the in-office standard of care (intralesional triamcinolone acetonide injections) into a home setting. The ClearPen controls dosage, depth, and volume of injection, and the company is advancing toward Phase 2 clinical trials in 2026.

Product and service1 record
1ClearPen™ System
CategoryDermatology Therapeutics
Description

The ClearPen™ System is a drug-device combination product combining the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device designed to enable patients to self-administer intralesional acne injections at home for the treatment of moderate to severe inflammatory acne lesions. The device controls dosage, depth, and volume of injection to replicate the in-office standard of care.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Lifecore Biomedical has entered into a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001 drug candidate for planned Phase 2 clinical trials in 2026. This is the second agreement between the companies, with Lifecore having previously provided formulation and process optimization services for the DT-001 program. The agreement supports Lifecore's expansion beyond ophthalmic therapies into autoinjector technologies while Indomo develops DT-001 for use with its ClearPen self-injection device.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Unilife Corporation
TypeDirect peer
Description

Developer of injectable drug-delivery devices including auto-injectors and intradermal delivery systems. Directly comparable to ClearPen's drug-device architecture, and another of CEO Rick Bente's former companies.

TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with leading prescription acne franchises (Epiduo, Differin, etc.). Comparable as the incumbent leader in prescription acne therapeutics that Indomo's intralesional platform would compete with or partner alongside.

TypeDirect peer
Description

Maker of the Omnipod tubeless insulin pump — a wearable drug-delivery device for patient self-administration at home. Directly comparable to Indomo's ClearPen as a patient-facing injectable/wearable drug-device combination, and notably CEO Rick Bente's former company.

TypeDirect peer
Description

Tele-dermatology platform providing custom prescription acne and skincare treatments shipped directly to consumers. Comparable as a direct-to-consumer acne-treatment competitor pursuing the at-home convenience thesis.

TypeBroad incumbent
Description

Dermatology division of Bausch Health with established prescription acne portfolio (Onexton, Retin-A Micro, etc.). Comparable as a broad incumbent dermatology player whose portfolio overlaps with Indomo's inflammatory acne indication.

TypeDirect peer
Description

Direct-to-consumer tele-health platform offering prescription dermatology treatments including for acne. Comparable as a consumer-facing acne/dermatology brand with at-home delivery, and was co-founded by Indomo's Chairman Jack Abraham — providing a direct strategic and operational template.

TypeDirect peer
Description

Consumer acne-care brand selling patches and skincare direct to consumers; Indomo's COO Cara Davis was part of Starface's founding team. Comparable as a consumer-first acne brand with overlapping end-customer base.

TypeBroad incumbent
Description

Major supplier of elastomeric components, containment systems, and drug-delivery device platforms for injectable therapeutics. Comparable as a broad incumbent in the injectable drug-delivery infrastructure layer that Indomo's ClearPen competes against or partners with.

TypeBroad incumbent
Description

Pharmaceutical incumbent with a major aesthetics and dermatology franchise (including former Allergan assets). Comparable as a broad incumbent whose aesthetics/dermatology portfolio overlaps with Indomo's intralesional corticosteroid positioning, and notably connected via board observer Brent Saunders (former Allergan CEO).

TypeDirect peer
Description

Tele-dermatology platform offering custom prescription acne and rosacea treatments prescribed online and delivered to patients. Comparable as a consumer-facing prescription dermatology platform with overlapping patient acquisition motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Indomo

Dermatology Therapeuticsindomotx.com

Indomo is a clinical-stage therapeutics company developing the ClearPen System, a drug-device combination of an intradermal self-injection device and DT-001 corticosteroid, enabling at-home self-administered treatment of inflammatory acne lesions for the 50 million Americans affected by acne.

What Indomo does

Indomo (doing business as ACOM Labs, Inc., a Delaware-incorporated corporation headquartered in Boston with a San Francisco mailing address) is a clinical-stage therapeutics company developing a drug-device combination platform for at-home treatment of inflammatory acne lesions. The company's core offering, the ClearPen™ System, pairs a novel intradermal self-injection device (ClearPen) with a corticosteroid drug candidate (DT-001, based on triamcinolone acetonide) to enable patients to self-administer intralesional injections at home, replicating a procedure that has been the in-office dermatology standard of care for 50+ years and is recommended by the American Academy of Dermatology.

The underlying technology combines a patented intradermal self-injection mechanism designed to control dosage, depth, and volume with a reformulated corticosteroid drug candidate. Indomo has completed two investigator-led trials and a sponsored n=56 trial demonstrating equivalence between patient self-injection and provider injection with zero adverse events and significant lesion improvement reported by over two-thirds of participants within 24 hours. Phase 2 clinical trials are planned for 2026, with DT-001 manufacturing contracted to Lifecore Biomedical under a development services agreement signed in March 2026.

The company is pre-revenue with no commercial products, no FDA approval, and no disclosed pricing. Its go-to-market motion is product-led, targeting the underserved patient population of 50 million Americans affected by acne who lack access to dermatologists or prefer at-home treatment. Indomo maintains a clinical trial waitlist as its primary mid-funnel conversion mechanism, and the planned commercial model appears to be direct-to-consumer distribution of the combined device-plus-drug system. The company raised $25 million in late 2025 led by Atomic, Foresite Capital, and Polaris Partners to fund clinical development and platform expansion.

Indomo firmographics

Firmographics
Name
Indomo
Legal name
ACOM Labs, Inc.
Website
https://indomotx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Indomo is a clinical-stage therapeutics company developing the ClearPen System, a drug-device combination of an intradermal self-injection device and DT-001 corticosteroid, enabling at-home self-administered treatment of inflammatory acne lesions for the 50 million Americans affected by acne.
Ownership category
akta.pro rank

Indomo industry classification

Industry
Product category
Dermatology Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Pharmaceutical Preparation Manufacturing (325412)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Drug-device combination
  • Intradermal injection
  • Acne therapeutics
  • Self-injection devices
  • Dermatology treatments

Where Indomo is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Indomo business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. ClearPen System (DT-001 + Device): Clinical-stage company developing a drug-device combination product. The ClearPen system combines DT-001 corticosteroid with a self-injection device for at-home acne treatment. Revenue model not yet disclosed as products are under development and have not been evaluated by FDA or any regulatory authority.

Go-to-market motion2 records

Marketing channels4 records

Indomo product offering

Product offering

Core offering

Indomo is developing the ClearPen™ System, a drug-device combination platform that pairs the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device. The system is designed to enable patients to self-administer intralesional acne injections at home, replicating the in-office standard of care for moderate to severe inflammatory acne lesions. Indomo's products are currently under development and have not been evaluated by the FDA or any regulatory health authority.

Product overview

Indomo is a clinical-stage therapeutics company developing a drug-device combination platform for at-home dermatological treatments. The company's primary offering consists of the ClearPen™ intradermal self-injection device combined with DT-001, a corticosteroid drug candidate. Together, this device-plus-drug platform enables patients to self-administer intralesional injections for inflammatory acne lesions at home, shifting the in-office standard of care (intralesional triamcinolone acetonide injections) into a home setting. The ClearPen controls dosage, depth, and volume of injection, and the company is advancing toward Phase 2 clinical trials in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • ClearPen™ System The ClearPen™ System is a drug-device combination product combining the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device designed to enable patients to self-administer intralesional acne injections at home for the treatment of moderate to severe inflammatory acne lesions. The device controls dosage, depth, and volume of injection to replicate the in-office standard of care.

Quantifiable outcome

  • Over two-thirds of participants reported significant improvement of lesion within 24 hours
  • +2 more outcomes

Companies that use Indomo

Customer profile

Segments1 record

Ideal customer profiles1 record

Indomo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Indomo partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lifecore BiomedicalcoreStrategic or Co-development Partner · 4 March 2026Lifecore Biomedical has entered into a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001 drug candidate for planned Phase 2 clinical trials in 2026. This is the second agreement between the companies, with Lifecore having previously provided formulation and process optimization services for the DT-001 program. The agreement supports Lifecore's expansion beyond ophthalmic therapies into autoinjector technologies while Indomo develops DT-001 for use with its ClearPen self-injection device.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Indomo competitors and assessment

Company assessment

Direct peers

  • Unilife Corporation: Developer of injectable drug-delivery devices including auto-injectors and intradermal delivery systems. Directly comparable to ClearPen's drug-device architecture, and another of CEO Rick Bente's former companies.
  • Insulet Corporation: Maker of the Omnipod tubeless insulin pump — a wearable drug-delivery device for patient self-administration at home. Directly comparable to Indomo's ClearPen as a patient-facing injectable/wearable drug-device combination, and notably CEO Rick Bente's former company.
  • Curology: Tele-dermatology platform providing custom prescription acne and skincare treatments shipped directly to consumers. Comparable as a direct-to-consumer acne-treatment competitor pursuing the at-home convenience thesis.
  • Hims & Hers Health: Direct-to-consumer tele-health platform offering prescription dermatology treatments including for acne. Comparable as a consumer-facing acne/dermatology brand with at-home delivery, and was co-founded by Indomo's Chairman Jack Abraham — providing a direct strategic and operational template.
  • Starface: Consumer acne-care brand selling patches and skincare direct to consumers; Indomo's COO Cara Davis was part of Starface's founding team. Comparable as a consumer-first acne brand with overlapping end-customer base.
  • Apostrophe (tele-dermatology): Tele-dermatology platform offering custom prescription acne and rosacea treatments prescribed online and delivered to patients. Comparable as a consumer-facing prescription dermatology platform with overlapping patient acquisition motion.

Broad incumbents

  • Galderma: Global dermatology-focused pharmaceutical company with leading prescription acne franchises (Epiduo, Differin, etc.). Comparable as the incumbent leader in prescription acne therapeutics that Indomo's intralesional platform would compete with or partner alongside.
  • Bausch Health (Ortho Dermatologics): Dermatology division of Bausch Health with established prescription acne portfolio (Onexton, Retin-A Micro, etc.). Comparable as a broad incumbent dermatology player whose portfolio overlaps with Indomo's inflammatory acne indication.
  • West Pharmaceutical Services: Major supplier of elastomeric components, containment systems, and drug-delivery device platforms for injectable therapeutics. Comparable as a broad incumbent in the injectable drug-delivery infrastructure layer that Indomo's ClearPen competes against or partners with.
  • AbbVie (Allergan Aesthetics): Pharmaceutical incumbent with a major aesthetics and dermatology franchise (including former Allergan assets). Comparable as a broad incumbent whose aesthetics/dermatology portfolio overlaps with Indomo's intralesional corticosteroid positioning, and notably connected via board observer Brent Saunders (former Allergan CEO).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Indomo social profiles

Digital presence

Indomo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Indomo leadership team

Management profile

Number of profiles

Profiles11 records

Indomo funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Indomo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indomo

What does Indomo do?

Indomo is developing the ClearPen™ System, a drug-device combination platform that pairs the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device. The system is designed to enable patients to self-administer intralesional acne injections at home, replicating the in-office standard of care for moderate to severe inflammatory acne lesions. Indomo's products are currently under development and have not been evaluated by the FDA or any regulatory health authority.

Is Indomo a public or private company?

Indomo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Indomo founded?

Indomo was founded in 2021. It employs 1 to 10 people.

Where is Indomo based?

Indomo is headquartered in San Francisco, United States, in the North America region.

How does Indomo make money?

One revenue line is on record: clearPen System (DT-001 + Device).

Who are Indomo's main competitors?

Direct peers on record are Unilife Corporation, Insulet Corporation, Curology, Hims & Hers Health, Starface and Apostrophe (tele-dermatology). Broad incumbents are Galderma, Bausch Health (Ortho Dermatologics), West Pharmaceutical Services and AbbVie (Allergan Aesthetics).

Does Indomo have an API?

No public API is recorded for Indomo.

What industry is Indomo in?

Indomo's product category is Dermatology Therapeutics. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comLifecore to manufacture acne treatment batches for Indomo By Investing.comLifecore Biomedical has entered into a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid drug candidate for treating inflammatory acne lesions, to support studies for anticipated Phase 2 clinical trials in 2026. This is the second agreement between the companies, with Lifecore having previously provided formulation and process optimization services for the DT-001 program. The agreement supports Lifecore's strategy to expand beyond ophthalmic therapies and strengthen its presence in autoinjector technologies, while Indomo is developing DT-001 for use with its investigational ClearPen self-injection device.GlobeNewswireLifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne TreatmentLifecore Biomedical and Indomo signed a development services agreement for Indomo's corticosteroid drug DT-001, with Lifecore producing engineering and clinical batches. The drug will be combined with Indomo's ClearPen device for at-home acne treatment, with planned Phase 2 trials in 2026.YahooLifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne TreatmentLifecore Biomedical and Indomo announced a new development services agreement under which Lifecore will produce engineering and clinical batches of Indomo's DT-001 drug candidate for planned Phase 2 clinical trials in 2026. DT-001 is being developed for use with Indomo's ClearPen intradermal self-injection device as an at-home treatment for inflammatory acne lesions, targeting the underserved market of 50 million Americans affected by acne. This collaboration represents Lifecore's continued expansion beyond its traditional ophthalmic therapies into autoinjector technologies.Crunchbase News5 Interesting Startup Deals You May Have Missed: Robotic Hands, An Artificial Retina Developed In Space, A GenAI Sticker Printer For Kids, And MoreThis article summarizes five distinct startup funding rounds in the hardware and biotech sectors, including Indomo's $25 million raise for at-home acne treatment devices and Mimic Robotics' $16 million for industrial robotic limbs. Other featured deals include LambdaVision securing $7 million to develop artificial retinas using microgravity manufacturing on the International Space Station, Stickerbox raising $7 million for an AI-powered sticker printer for children, and Milvus Advanced obtaining $6.9 million for lab-grown rare metal alternatives.Pulse 2.0Indomo: $25 Million Raised To Bring At-Home Injectable Treatment For Acne Into The MainstreamBoston-based clinical-stage therapeutics company Indomo has raised $25 million in a funding round led by Atomic, Foresite Capital, and Polaris Partners to advance its at-home injectable therapy for inflammatory acne. The company's debut product, ClearPen, combines a microneedle self-injection device with triamcinolone acetonide, a corticosteroid traditionally administered in dermatology offices. The funding will support Phase 2 clinical trials and platform development as the company seeks to address a nationwide shortage of dermatologists, with some regions averaging one dermatologist per 28,000 people.FinSMEsIndomo Raises $25M in FundingIndomo, a Boston-based therapeutics company, raised $25M in funding from Atomic, Foresite Capital, Polaris Partners, and others. The company will use the funds to support its Phase 2 clinical trials and device platform development. Its debut product, ClearPen, combines therapeutics with a microneedle device for at-home acne treatment.Global Cosmetics NewsIndomo Raises US$25 Million for At-Home Injectable Acne TreatmentBoston-based therapeutics company Indomo has secured US$25 million in funding to develop ClearPen, an at-home investigational injectable therapy combining a microneedle self-injection device with triamcinolone acetonide for inflammatory acne treatment. The funding round was backed by Atomic, Foresite Capital, and Polaris Partners, with the company led by CEO Rick Bente and co-founder Jack Abraham. Indomo plans to use the proceeds to advance Phase 2 clinical trials and expand its microneedle delivery platform to other skin conditions.HIT ConsultantIndomo Emerges from Stealth with $25M for At-Home Injectable Acne TherapyIndomo, a therapeutics company focusing on at-home dermatology treatments, announced emerging from stealth with $25 million in funding led by Atomic, Foresite Capital, and Polaris Partners. The funding will support phase 2 clinical trials of its ClearPen™, an investigational self-injection device designed for treating inflammatory acne.